Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in SYRE held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 11.8M | $594.2M | +1.2% | 3.405% | 0.03% |
| 2 | BlackRock, Inc. | 5.5M | $278.5M | -0.0% | 1.596% | 0.00% |
| 3 | RTW INVESTMENTS, LP | 4.2M | $210.4M | 0.0% | 1.206% | 2.09% |
| 4 | Fairmount Funds Management LLC | 4.0M | $202.7M | 0.0% | 1.161% | 14.64% |
| 5 | PERCEPTIVE ADVISORS LLC | 3.8M | $190.8M | +23.3% | 1.093% | 3.77% |
| 6 | VR Adviser, LLC | 3.7M | $185.9M | 0.0% | 1.065% | 6.94% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3.1M | $154.2M | — | 0.884% | 0.00% |
| 8 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.8M | $140.8M | -3.2% | 0.806% | 1.03% |
| 9 | STATE STREET CORP | 2.6M | $131.5M | +15.2% | 0.753% | 0.00% |
| 10 | Paradigm Biocapital Advisors LP | 2.0M | $98.7M | +33.4% | 0.566% | 2.02% |
| 11 | COMMODORE CAPITAL LP | 1.9M | $96.5M | -19.9% | 0.553% | 5.58% |
| 12 | Remedium Capital Partners, LLC | 1.9M | $96.2M | +31.0% | 0.551% | 30.09% |
| 13 | TCG Crossover Management, LLC | 1.9M | $95.9M | 0.0% | 0.549% | 2.74% |
| 14 | TANG CAPITAL MANAGEMENT LLC | 1.9M | $95.4M | 0.0% | 0.547% | 4.85% |
| 15 | WELLINGTON MANAGEMENT GROUP LLP | 1.8M | $92.0M | +17.8% | 0.527% | 0.02% |
| 16 | Capital International Investors | 1.7M | $88.1M | -50.0% | 0.505% | 0.02% |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 1.7M | $86.8M | +3.7% | 0.497% | 0.01% |
| 18 | JANUS HENDERSON GROUP PLC | 1.7M | $83.6M | -9.4% | 0.479% | 0.04% |
| 19 | RA CAPITAL MANAGEMENT, L.P. | 1.6M | $81.8M | 0.0% | 0.469% | 0.87% |
| 20 | Affinity Asset Advisors, LLC | 1.3M | $64.5M | -10.7% | 0.370% | 3.75% |
| 21 | BANK OF AMERICA CORP /DE/ | 1.2M | $61.9M | +192.6% | 0.355% | 0.00% |
| 22 | BAKER BROS. ADVISORS LP | 1.0M | $50.4M | 0.0% | 0.289% | 0.29% |
| 23 | BRAIDWELL LP | 933K | $47.1M | -42.9% | 0.270% | 1.57% |
| 24 | FRANKLIN RESOURCES INC | 883K | $44.5M | -20.4% | 0.255% | 0.01% |
| 25 | Caligan Partners LP | 878K | $44.3M | — | 0.254% | 3.08% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in SYRE — a direct measure of their conviction.
Filings activity in SYRE during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 196 | +27% | 14.54% | +5.41 pp | $4.06B | +59% |
| Q4 2025 | 154 | +15% | 9.13% | +5.32 pp | $2.55B | +139% |
| Q3 2025 | 134 | +3.1% | 3.81% | +0.47 pp | $1.07B | +14% |
| Q2 2025 | 130 | +0.0% | 3.34% | 0.22 pp | $933M | 6.1% |
| Q1 2025 | 130 | 1.5% | 3.56% | 1.28 pp | $994M | 26% |
| Q4 2024 | 132 | +11% | 4.84% | 0.43 pp | $1.35B | 8.2% |
| Q3 2024 | 119 | +10% | 5.27% | +1.13 pp | $1.47B | +27% |
| Q2 2024 | 108 | — | 4.14% | — | $1.16B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying SYRE stock.
Based on Q1 2026 13F filings, institutional ownership of Spyre Therapeutics, Inc. stands at 14.5%, held across 196 reporting institutions.
FMR LLC is the largest reported institutional holder of SYRE, with approximately 11,781,024 shares worth $0.59B as of Q1 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of SYRE.
Our composite Smart Money Score for SYRE is 60 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
57 institutions opened new positions in SYRE during Q1 2026, while 15 fully exited. 121 added to existing positions and 16 trimmed.
SYRE institutional ownership rose by 5.41 percentage points quarter-over-quarter, with a net change of +42 holders.
The top 10 institutions account for 53.8% of all reported 13F value in SYRE, and the top 25 account for 81.6%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Spyre Therapeutics, Inc. (SYRE) Institutional Ownership